These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25773496)

  • 1. GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial.
    Dobbins R; Byerly R; Gaddy R; Gao F; Mahar K; Napolitano A; Ambery P; Le Monnier de Gouville AC
    Eur J Pharmacol; 2015 May; 755():95-101. PubMed ID: 25773496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.
    Dobbins RL; Shearn SP; Byerly RL; Gao FF; Mahar KM; Napolitano A; Nachbaur GJ; Le Monnier de Gouville AC
    Diabetes Obes Metab; 2013 Nov; 15(11):1013-21. PubMed ID: 23701262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.
    Sprecher D; Maxwell M; Goodman J; White B; Tang CM; Boullay V; de Gouville AC
    Eur J Pharmacol; 2015 Jun; 756():1-7. PubMed ID: 25773497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
    Olson EJ; Mahar KM; Haws TF; Fossler MJ; Gao F; de Gouville AC; Sprecher DL; Lepore JJ
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):871-883. PubMed ID: 31268250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
    Mu Y; Pan C; Fan B; Hehnke U; Zhang X; Zhang X; Wang X; Liu J; Zhang Y; Du J; Ma J; Gong Y
    Diabetes Res Clin Pract; 2017 Feb; 124():48-56. PubMed ID: 28088030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation.
    Fujioka K; Pans M; Joyal S
    Clin Ther; 2003 Feb; 25(2):515-29. PubMed ID: 12749511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S; Sothiratnam R; Sari R; Andersen H; Hiort LC; Rao P
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus.
    Pan C; Xing X; Han P; Zheng S; Ma J; Liu J; Lv X; Lu J; Bader G;
    Diabetes Obes Metab; 2012 Aug; 14(8):737-44. PubMed ID: 22369287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
    Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
    Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
    Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
    Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J; Wysham C; Frías JP; Kaneko S; Lee CJ; Fernández Landó L; Mao H; Cui X; Karanikas CA; Thieu VT
    Lancet; 2021 Jul; 398(10295):143-155. PubMed ID: 34186022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial combination of linagliptin and metformin in patients with type 2 diabetes: efficacy and safety in a randomised, double-blind 1-year extension study.
    Haak T; Meinicke T; Jones R; Weber S; von Eynatten M; Woerle HJ
    Int J Clin Pract; 2013 Dec; 67(12):1283-93. PubMed ID: 24118640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
    Zhu D; Gan S; Liu Y; Ma J; Dong X; Song W; Zeng J; Wang G; Zhao W; Zhang Q; Li Y; Fang H; Lv X; Shi Y; Tian H; Ji L; Gao X; Zhang L; Bao Y; Lei M; Li L; Zeng L; Li X; Hou X; Zhao Y; Hu T; Ge X; Zhao G; Li Y; Zhang Y; Chen L
    Lancet Diabetes Endocrinol; 2018 Aug; 6(8):627-636. PubMed ID: 29735394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J; Anderson RJ; Rappaport EB
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.
    Yamada Y; Terauchi Y; Watada H; Nakatsuka Y; Shiosakai K; Washio T; Taguchi T
    Adv Ther; 2018 Mar; 35(3):367-381. PubMed ID: 29488152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.